Coenzyme Q10 and adverse effects of statins

Journal of Nutritional and Environmental Medicine

Volumn 14, Issue 1, 2004, Pages 17-28

  Chiang, Chern An ^a   Pella, Daniel ^b   Singh, Ram B ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c Medical Hospital and Research Centre Moradabad   (India)

Author keywords

Cerivastatin; Cholesterol; Statin toxicity; Ubiquinone

Indexed keywords

AMINOTRANSFERASE; AMIODARONE; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CISAPRIDE; CYCLOSPORIN; DICLOFENAC; EZETIMIBE; FELODIPINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; NICOTINIC ACID; NIFEDIPINE; OMEPRAZOLE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULODEXIDE; TOLBUTAMIDE; UBIDECARENONE; WARFARIN;

ARTHRALGIA; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDUSTRY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; FATIGUE; HUMAN; HYDROPHILICITY; HYPERLIPIDEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MENTAL DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; MYOSITIS; NEOPLASM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

EID: 2942596524     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.1080/13590840410001695158     Document Type: Review

References (34)

1. ACC/AHA/NHLBI Clinical Advisory on Stalins: clinical advisory on the use and safety of statins. JACC 2002; 40: 567-72.
2. Chong P, Seeger J, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400.
3. Bliznakov EG. Lipid lowering drugs (statins), cholesterol, and coenzyme Q10 - The Baycol case - a modern Pandora's box. Biomed Pharmacother 2002; 56: 56-9.
4. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid lowering drugs and risk of myopathy: a population based follow up study. Epidemiology 2001; 12: 565-9.
5. Staffa JA, Green L. Cerivastatin and reports of rhabdomyolysis. N Engl J Med 2002; 346: 565-70.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
7. Gaist D, Jeppesen U, Anderson M et al. Statins and risk of poluneuropathy: a case control study. Neurology 2002; 58: 1333-7.
8. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383-5.
9. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemphibrozil combination therapy. JAMA 1990; 264: 71-5.
10. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996; 14: 11-24.
11. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitors monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-59.
12. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-97.
13. Pella D, Singh RB, Tomlinson B, Kong CW. Coronary artery disease in developing and newly industrialized countries: a scientific statement of the International College of Cardiology. In: Choklingham A, Berkowitz I, Singal PK, Dhalla NS (eds) Frontiers in Cardiovascular Health. Boston: Kluwer, 2003, 473-88.
14. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
15. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
16. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9.
17. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a metaanalysis of randomized, controlled trials. JAMA 1999; 282: 2340-6.
18. Scandinavian Simstatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
19. Longterm Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Longterm Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 2003; 339: 1349-57.
20. Shepherd Jthe PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized, controlled trial. Lancet 2002; 360: 1623-30.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of individuals: cholesterol lowering with simvastatin in 20,536 high-risk a randomized, placebo controlled trial. Lancet 2002; 360: 7-22.
22. Nelson DR, Katamaki T, Waxman DL et al. The P 450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12: 1-51.
23. Nebert DW. The P 450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991; 10: 1-14.
24. London SF, Gross KF, Ringel SP. Cholesterol lowering agent myopathy. Neurology 1991; 41: 1159-60.
25. Mortensen SA, Leth A, Agner E et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG CoA reductase inhibitors. Mol Aspects Med 1997; 18 (Suppl. S): S137-44.
26. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984; 144: 1045-57.
27. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
28. Ballantyne CM. Evolving concepts and new approach for management of hyperlipidemia. Eur Heart J 2002; 4(Suppl. J): J1-3.
29. Pella D, Rybár R, Valočik G, Petrášová D, Trejbal D, Mitro P. Secondary prevention of atherosclerosis by combined treatment with sulodexide and fluvastatin. Cardiovascular Diseases. Bologna: Monduzzi Editore, 2002, 289-93.
30. de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85.
31. Singh RB, Dubnov O, Niaz MA et al. The effect of an Indo-Mediterranean diet on the progression of coronary artery disease in high risk patients. The Indo-Mediterranean Diet Heart Study. Lancet 2002; 360: 1455-61.
32. Hoerger JG. US National Health and Nutrition Examination Survey III. Am J Cardiol 1998; 82: 61-5.
33. Singh RB, Neki NS, Kartikey K, Pella D et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75-82.
34. Editorial. How a statin might destroy a drug company. Lancet 2003; 361: 793.